Sunil Healthcare

Which are the latest news on Sunil Healthcare?

Why is Sunil Healthcare Ltd falling/rising?

As of 24-Jun, Sunil Healthcare Ltd's stock price is rising to Rs 70.92, reflecting a 4.23% increase. This rise is supported by strong recent performance and positive technical indicators, despite a decline in investor participation.

As of 24-Jun, Sunil Healthcare Ltd's stock price is rising, currently at Rs 70.92, reflecting a change of Rs 2.88 or 4.23% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the Sensex, gaining 9.78% while the benchmark index has declined by 0.21%. Additionally, in the last month, the stock has increased by 11.33%, significantly outperforming the Sensex's 2.09% rise.<BR><BR>Today's performance highlights a strong start, as the stock opened with a gain of 4.35% and reached an intraday high of Rs 71. The stock has been on a consecutive gain streak for the last two days, accumulating a total return of 4.41% during this period. Furthermore, Sunil Healthcare is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 61.73% compared to the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading, which may contribute to its current upward trajectory. Overall, the combination of strong recent performance, positive technical indicators, and market outperformance supports the rise in Sunil Healthcare Ltd's stock price.

Should I buy, sell or hold Sunil Healthcare Ltd?

How big is Sunil Healthcare?

As of 10th June, Sunil Healthcare Ltd has a market capitalization of 65.00 Cr, with recent net sales of 87.72 Cr and a net profit of 4.02 Cr. Shareholder's funds are 67.07 Cr, and total assets amount to 161.94 Cr as of March 2025.

As of 10th June, Sunil Healthcare Ltd has a market capitalization of 65.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Sunil Healthcare reported Net Sales of 87.72 Cr and a Net Profit of 4.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 67.07 Cr and Total Assets of 161.94 Cr.

Who are in the management team of Sunil Healthcare?

The management team of Sunil Healthcare includes Anil Kumar Khaitan (Chairman & Managing Director), Sanjay Kumar Kaushik (Non-Executive Director), Rakesh Mohan (Non-Executive & Independent Director), and several others, all contributing to the company's strategic direction and compliance. For more details on specific members or roles, please ask!

The management team of Sunil Healthcare includes the following individuals:<BR><BR>1. **Anil Kumar Khaitan** - Chairman & Managing Director<BR>2. **Sanjay Kumar Kaushik** - Non-Executive Director<BR>3. **Rakesh Mohan** - Non-Executive & Independent Director<BR>4. **Santosh Kumar Sharma** - Company Secretary<BR>5. **Harish Pal Kumar** - Non-Executive & Independent Director<BR>6. **Krishna Venkatachalam Ranjan** - Non-Executive & Non-Independent Director<BR>7. **Mudita Chaturvedi** - Additional Non-Executive Director<BR>8. **Bejon Kumar Misra** - Non-Executive & Independent Director<BR>9. **Satyendu Pattnaik** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations. If you need more specific information about any of the members or their roles, feel free to ask!

Who are the peers of the Sunil Healthcare?

Sunil Healthcare's peers include Phaarmasia, Source Natural, and Samrat Pharma, among others. In terms of management risk, Source Natural and Vasundhara Rasy. are excellent, while Sunil Healthcare has below average growth and a below average capital structure, with a 1-year return of -25.61%.

Peers: The peers of Sunil Healthcare are Phaarmasia, Source Natural, Vineet Laborator, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Vasundhara Rasy., JFL Life, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural and Vasundhara Rasy., while Average management risk is found at Samrat Pharma, Asston Pharmaceu, and JFL Life, and the rest have Below Average management risk. Good growth is seen at Sunil Healthcare and JFL Life, Average growth at Ajooni Biotech, and Below Average growth at Phaarmasia, Source Natural, Vineet Laborator, Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Vasundhara Rasy., and the rest. Excellent capital structure is noted at Samrat Pharma, Good capital structure at Source Natural, Biofil Chemicals, and Ajooni Biotech, Average capital structure at Asston Pharmaceu, and Below Average capital structure at Phaarmasia, Vineet Laborator, Sunil Healthcare, Vivo Bio Tech, Vasundhara Rasy., and the rest.<BR><BR>Return Snapshot: Phaarmasia has the highest 1-year return at 227.71%, while Source Natural has the lowest at -42.15%, with Sunil Healthcare's 1-year return at -25.61% being better than Source Natural but worse than Phaarmasia. Additionally, the six-month returns are negative for Samrat Pharma, Vivo Bio Tech, and Sunil Healthcare.

What does Sunil Healthcare do?

Sunil Healthcare Ltd manufactures Empty Hard Gelatin and HPMC Capsules, operating in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 20 Cr and a net profit of 2 Cr, with a market cap of INR 65 Cr.

Overview:<BR>Sunil Healthcare Ltd is a company engaged in the manufacture of Empty Hard Gelatin Capsules and HPMC Capsules Shell, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>History:<BR>Incorporated in 1973, Sunil Healthcare Ltd was formerly known as Sunil Synchem Ltd. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 20 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 65 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 15.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.77<BR>- Return on Equity: 5.95%<BR>- Price to Book: 0.96<BR><BR>Contact Details:<BR>Address: 38E/252-A 1st Flr, Vijay Tower Shahpurjat New Delhi New Delhi : 110049<BR>Tel: 91-11-49435555<BR>Email: info@sunilhealthcare.com<BR>Website: http://www.sunilhealthcare.com

When is the next results date for Sunil Healthcare Ltd?

The next results date for Sunil Healthcare Ltd is 29 May 2026.

The next results date for Sunil Healthcare Ltd is scheduled for 29 May 2026.

Are Sunil Healthcare Ltd latest results good or bad?

Sunil Healthcare Ltd's latest results show a return to profitability with a net profit of ₹1.00 crore and revenue growth of 16.09% year-on-year; however, concerns remain due to low return on equity, high debt levels, and stock underperformance, suggesting caution for investors.

Sunil Healthcare Ltd's latest results present a mixed picture. On the positive side, the company has shown a return to profitability with a net profit of ₹1.00 crore in Q2 FY26, reflecting a 9.89% increase quarter-on-quarter. Additionally, revenue grew by 16.09% year-on-year to ₹23.52 crore, indicating a stabilizing demand for its gelatin capsule products after a challenging period.<BR><BR>The operating margin also improved significantly to 16.67%, up from 14.49% in the previous quarter, suggesting better operational efficiency. However, despite these improvements, there are significant concerns. The return on equity (ROE) remains low at 2.55%, indicating weak capital efficiency, and the company continues to face high debt levels, with a debt-to-EBITDA ratio of 6.68 times. This raises questions about its long-term viability and ability to service its debt.<BR><BR>Moreover, the stock has been underperforming, down 16.13% over the past year compared to the Sensex's gain of 7.07%. The technical indicators are also mildly bearish, with the stock trading below key moving averages.<BR><BR>In summary, while there are signs of operational recovery, the overall financial health of Sunil Healthcare is still concerning due to weak return ratios, high leverage, and persistent stock underperformance. Investors should weigh these factors carefully when considering the company's outlook.

Is Sunil Healthcare overvalued or undervalued?

As of November 20, 2025, Sunil Healthcare is considered overvalued with a high PE ratio of 42.04 and an EV to EBITDA of 10.06, despite a low PEG ratio of 0.18, indicating inefficiencies in capital utilization and underperformance compared to industry peers and the Sensex.

As of 20 November 2025, Sunil Healthcare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered overvalued based on its high PE ratio of 42.04, which significantly exceeds the industry average. Additionally, its EV to EBITDA stands at 10.06, while its ROCE is only 5.00%, suggesting inefficiencies in capital utilization compared to peers.<BR><BR>In comparison to its industry peers, Sunil Healthcare's valuation metrics are notably higher; for instance, Sun Pharma has a PE ratio of 36.94 and an EV to EBITDA of 24.4, while Cipla, another attractive peer, has a PE of 22.72 and an EV to EBITDA of 16.07. The PEG ratio for Sunil Healthcare is also low at 0.18, indicating potential growth relative to its price, but this does not sufficiently offset the concerns raised by its high valuation ratios. Furthermore, the company's stock has underperformed relative to the Sensex over various time frames, including a year-to-date return of -9.08% compared to the Sensex's 9.59%.

How has been the historical performance of Sunil Healthcare?

Sunil Healthcare's historical performance shows a decline in net sales and profits, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit after tax turning negative from 6.68 Cr to -1.42 Cr. However, cash flow from operating activities improved from 7.00 Cr to 11.00 Cr during the same period.

Answer:<BR>The historical performance of Sunil Healthcare shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sunil Healthcare's net sales have decreased from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25. The company's total expenditure also declined from 94.33 Cr in Mar'23 to 73.16 Cr in Mar'25, indicating cost management efforts. Operating profit, which reached 20.66 Cr in Mar'23, fell to 11.60 Cr by Mar'25, while profit before tax transitioned from a positive 9.48 Cr in Mar'23 to a negative 1.22 Cr in Mar'25. Consequently, the profit after tax also turned negative, from 6.68 Cr in Mar'23 to -1.42 Cr in Mar'25. The company's total liabilities increased from 120.79 Cr in Mar'23 to 161.94 Cr in Mar'25, while total assets rose from 120.79 Cr to 161.94 Cr in the same period. Cash flow from operating activities showed improvement, moving from 7.00 Cr in Mar'23 to 11.00 Cr in Mar'25, despite the overall cash flow from financing activities being negative in Mar'25.

What is the technical trend for Sunil Healthcare?

As of June 6, 2025, Sunil Healthcare's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 6 June 2025, the technical trend for Sunil Healthcare has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the bearish stance. Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the complexity. The KST is mildly bullish weekly but mildly bearish monthly, and there are no clear trends indicated by Dow Theory. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Who are the top shareholders of the Sunil Healthcare?

The top shareholder of Sunil Healthcare is Anil Kumar Khaitan, who holds 57.95% of the shares. The highest public shareholder is Shailesh Kumar with 5.86%, while individual investors collectively own 17.85%.

The top shareholders of Sunil Healthcare are primarily the promoters, with Anil Kumar Khaitan holding the largest share at 57.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Shailesh Kumar, who owns 5.86% of the shares. Additionally, individual investors collectively hold 17.85% of the company's shares.

Has Sunil Healthcare declared dividend?

No Dividend History Available